A Study to Evaluate Gut Microbiome with POEMS Syndrome and Other Plasma Cell Disorders

Overview

About this study

The characteristics and role of gut microbiome rare plasma cell disorders- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) and amyloid light-chain (AL) amyloidosis, have not been explored; and their pathophysiology is quite elusive. To help understand rare plasma cell disorders and its association with gut microbiome, we will study the stool samples of newly diagnosed POEMS patients and AL amyloidosis and compare it with patients with newly diagnosed monoclonal gammopathy of undetermined significance and multiple myeloma as well as healthy controls. Moreover, gut microbiome in newly diagnosed POEMS patients will be compared to POEMS patients in remission. It is our overall hypothesis that in POEMS patients the gut microbiome signature will differ between active disease (at diagnosis) and inactive disease (in remission), and the gut microbiome in POEMS patients will be different from patients with other plasma cell disorders and healthy controls

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Men and women above 18 years of age.
  • Diagnosed with POEMS syndrome (newly diagnosed or in remission) or with newly diagnosed multiple myeloma or with monoclonal gammopathy of undetermined significance or amyloid light-chain (AL) amyloidosis or healthy controls from their households.

Exclusion Criteria:

  • Individuals under 18 years of age.
  • Pregnant women.
  • Substance abusers.
  • Individuals who used antibiotics in the 3 months prior to the study participation.
  • Individuals with chronic gastrointestinal disorder, or who had undergone gastrointestinal interventions in the past 2 years (surgery, endoscopies etc.).
  • Individuals who had undergone chemotherapy (including anti-plasma cell treatment and steroids, except POEMS patients in remission) or radiation treatment for cancer within the last 2 years or had active cancer (other than plasma cell disorder).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Angela Dispenzieri, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Ann Engebretson L.P.N.

(507) 293-1965

Engebretson.Ann@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20515796

Mayo Clinic Footer